Literature DB >> 8405467

In vitro activation of pro-cathepsin B by three serine proteinases: leucocyte elastase, cathepsin G, and the urokinase-type plasminogen activator.

V Dalet-Fumeron1, N Guinec, M Pagano.   

Abstract

In vitro activation of pro-cathepsin B purified from ascitic fluid of ovarian carcinomas by serine proteinases was studied. Both elastase and cathepsin G from human leucocytes were found to be activators, on the basis of generation of cathepsin B activity and processing of the precursor. These results represent a new cooperative pathway between cancer cells and host cells. The urokinase-type plasminogen activator activated pro-cathepsin B faster than leucocyte proteinases. A new relationship is emerging between the cysteine proteinases and the plasmin-activation system. Both pathways suggest an important role of cathepsin B in the proteolytic cascade associated with tumour invasion.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8405467     DOI: 10.1016/0014-5793(93)80643-9

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  10 in total

1.  Proteolytic mechanisms of cartilage breakdown: a target for arthritis therapy?

Authors:  D J Buttle; H Bramwell; A P Hollander
Journal:  Clin Mol Pathol       Date:  1995-08

2.  Cathepsin B: Basis Sequence: Mouse.

Authors:  Dora Cavallo-Medved; Kamiar Moin; Bonnie Sloane
Journal:  AFCS Nat Mol Pages       Date:  2011-04-10

Review 3.  Cathepsin B: multiple roles in cancer.

Authors:  Neha Aggarwal; Bonnie F Sloane
Journal:  Proteomics Clin Appl       Date:  2014-03-26       Impact factor: 3.494

4.  'Patchiness' and basic cancer research: unravelling the proteases.

Authors:  Surinder M Soond; Maria V Kozhevnikova; Andrey A Zamyatnin
Journal:  Cell Cycle       Date:  2019-06-24       Impact factor: 4.534

Review 5.  Proteases and antiproteases in chronic neutrophilic lung disease - relevance to drug discovery.

Authors:  Catherine M Greene; Noel G McElvaney
Journal:  Br J Pharmacol       Date:  2009-10       Impact factor: 8.739

6.  Lysosomal cathepsin B participates in the podosome-mediated extracellular matrix degradation and invasion via secreted lysosomes in v-Src fibroblasts.

Authors:  Chun Tu; Cesar F Ortega-Cava; Gengsheng Chen; Norvin D Fernandes; Dora Cavallo-Medved; Bonnie F Sloane; Vimla Band; Hamid Band
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

7.  Externalized decondensed neutrophil chromatin occludes pancreatic ducts and drives pancreatitis.

Authors:  Moritz Leppkes; Christian Maueröder; Sebastian Hirth; Stefanie Nowecki; Claudia Günther; Ulrike Billmeier; Susanne Paulus; Mona Biermann; Luis E Munoz; Markus Hoffmann; Dane Wildner; Andrew L Croxford; Ari Waisman; Kerri Mowen; Dieter E Jenne; Veit Krenn; Julia Mayerle; Markus M Lerch; Georg Schett; Stefan Wirtz; Markus F Neurath; Martin Herrmann; Christoph Becker
Journal:  Nat Commun       Date:  2016-03-11       Impact factor: 14.919

Review 8.  Cathepsin B in neurodegeneration of Alzheimer's disease, traumatic brain injury, and related brain disorders.

Authors:  Vivian Hook; Michael Yoon; Charles Mosier; Gen Ito; Sonia Podvin; Brian P Head; Robert Rissman; Anthony J O'Donoghue; Gregory Hook
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2020-04-17       Impact factor: 3.036

9.  TMEM106B drives lung cancer metastasis by inducing TFEB-dependent lysosome synthesis and secretion of cathepsins.

Authors:  Samrat T Kundu; Caitlin L Grzeskowiak; Jared J Fradette; Laura A Gibson; Leticia B Rodriguez; Chad J Creighton; Kenneth L Scott; Don L Gibbons
Journal:  Nat Commun       Date:  2018-07-16       Impact factor: 14.919

10.  Stable depletion of RUNX1-ETO in Kasumi-1 cells induces expression and enhanced proteolytic activity of Cathepsin G and Neutrophil Elastase.

Authors:  Caroline Schoenherr; Katharina Wohlan; Iris Dallmann; Andreas Pich; Jan Hegermann; Arnold Ganser; Denise Hilfiker-Kleiner; Olaf Heidenreich; Michaela Scherr; Matthias Eder
Journal:  PLoS One       Date:  2019-12-11       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.